Home  >  Products  >  BRCA1 (breast cancer 1, early onset) Blocking Peptide (the N terminal of BRCA1)(100ug)
BRCA1 (breast cancer 1, early onset) Blocking Peptide (the N terminal of BRCA1)(100ug)

BRCA1 (breast cancer 1, early onset) Blocking Peptide (the N terminal of BRCA1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-BRCA1 Antibody (ARP30434_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAPP33639
Size: 100ug
Weight: 76kDa
Gene: 672
Format: Lyophilized powder
Target: BRCA1, which functions as a tumor suppressor in human breast cancer cells, is a nuclear phosphoprotein which associates with RNA polymerase II holoenzyme. Mutations in BRCA1 are predicted to be responsible for approximately 45% of inherited breast cancer and more than 80% of inherited breast and ovarian cancer. BRCA1 may function as a transcriptional regulator, due to an amino terminal DNA-binding ring finger motif, nuclear localization signals, and an acidic carboxy terminal domain. BRCA1 is also a granin-like protein that functions as a secreted growth inhibitory protein. BRCA1 may normally serve as a negative regulator of mammary epithelial cell growth. This function is compromised in breast cancer either by direct mutation or by alterations in gene expression.
Alternative names: BRCAI; BRCC1; BROVCA1; IRIS; PSCP; RNF53
See Full Product Listings >